Cidara Therapeutics, Inc. — Proxy Solicitation & Information Statement 2022

Nov 29, 2022

DEFA14A 1 cdtxdefa14a2022-11.htm DEFINITIVE ADDITIONAL MATERIALS html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Document created using Wdesk Copyright 2022 Workiva Document

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ý

Filed by a Party other than the Registrant ¨

Check the appropriate box:

¨	Preliminary Proxy Statement
¨	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨	Definitive Proxy Statement
ý	Definitive Additional Materials
¨	Soliciting Material Pursuant to § 240.14a-12

CIDARA THERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

N/A

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply)

x	No fee required
¨	Fee paid previously with preliminary materials
¨	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

CIDARA THERAPEUTICS, INC.

6310 Nancy Ridge Drive, Suite 101

San Diego, CA 92121

SUPPLEMENT TO PROXY STATEMENT FOR SPECIAL MEETING OF STOCKHOLDERS

On November 29, 2022, Cidara Therapeutics, Inc. issued a press release related to Proposal 1 as described in the definitive proxy statement (the “Proxy Statement”) for its Special Meeting of Stockholders (the “Special Meeting”), to be held on December 15, 2022 at 8:00 a.m. Pacific Time. A copy of the Proxy Statement was filed with the Securities and Exchange Commission on November 10, 2022. A copy of the press release is included below.

THIS SUPPLEMENT, INCLUDING THE COPY OF THE PRESS RELEASE INCLUDED BELOW, SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.

Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split

November 29, 2022 08:00 ET | Source: Cidara Therapeutics, Inc.

SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Institutional Shareholder Services (ISS) and Glass Lewis and Co, LLC, two leading, independent proxy advisory firms, have both recommended that stockholders vote “FOR” the proposed reverse stock split at the Company’s upcoming Special Meeting of Stockholders, scheduled for Thursday, December 15, 2022 at 8:00 a.m. PST.

“We appreciate the recommendation of two leading independent proxy advisory firms advising our stockholders to vote in favor of the proposed reverse stock split,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We believe that the Board’s proposal is in the best interest of all shareholders and encourage each investor to follow the recommendations of ISS and Glass Lewis and vote “FOR” the proposal promptly.”

ISS and Glass Lewis are independent proxy advisory firms and do not have any business relationship with Cidara. Cidara did not engage or compensate either firm for their analysis or recommendations.

How to Vote:

Stockholders of record at the close of business on November 8, 2022 can vote by proxy or online during the Special Meeting. If you choose to submit a proxy, you may do so by telephone, via the internet or by mail.

Vote during meeting: Follow the provided instructions to join the Special Meeting at www.virtualshareholdermeeting.com/CDTX2022SM , starting at 8:00 a.m. PST on Thursday, December 15, 2022.

Vote by phone or by internet : Please refer to instructions provided by your bank or broker.

Vote by proxy card : Complete, sign and date the proxy card and return it promptly in the envelope provided.

About Cidara Therapeutics Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak ® platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com .

INVESTOR CONTACT: Brian Ritchie LifeSci Advisors (212) 915-2578 britchie@lifesciadvisors.com

MEDIA CONTACT: Patrick Bursey LifeSci Communications (203) 430-9545 pbursey@lifescicomms.com